HRES 1285

Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.

Bill status

Status
In committee
Sponsor
Rep. Diana DeGette [D-CO-1]
Cosponsors
50
Policy area
Health
Introduced
2026-05-14
Latest action
2026-05-14: Referred to the House Committee on Energy and Commerce.

Committee referrals

Recent actions

  • 2026-05-14: Referred to the House Committee on Energy and Commerce.
  • 2026-05-14: Submitted in House